 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...4041424344454647484950...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: SAKK 07/17: Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - May 3, 2023
P2, N=74, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Dec 2037 --> Dec 2041 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Enrollment closed, Tumor mutational burden: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) - May 3, 2023
P2, N=384, Active, not recruiting, Sponsor: Fondazione per la Medicina Personalizzata
Trial completion date: Dec 2037 --> Dec 2041 | Trial primary completion date: Apr 2023 --> Apr 2024 Recruiting --> Active, not recruiting
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Metastases: Update on patients with baseline CNS metastases CheckMate 227 (1L nivolumab + ipilimumab for advanced NSCLC) @JTOonline. With 5y f/u, nivo/ipi improved OS over chemo in this population (HR 0.63) with 5y PFS 16% (vs 6%) and 5y intracranial PFS 12% (vs 0%). https://t.co/Em0JWSJ3tN (Twitter) - May 3, 2023
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma. (Pubmed Central) - May 2, 2023
Patients who underwent CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC had a better prognosis than patients treated with nivolumab plus ipilimumab alone. These results suggest the efficacy of prior CN for synchronous mRCC with ICI combination therapy.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The ICI experience w/ pembro alone (n=1) was not good. TMB 214, blew right through pembro but excellent response to cabo. I now have a few of these on cabo. TMB probably means very little as a predictor post TMZ in pNETs. Curious to try ipi/nivo or even TKI/ICI. (Twitter) - May 2, 2023
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. (Pubmed Central) - May 2, 2023
Nivolumab add-on treatment showed less gastrointestinal and hematological adverse effects, compare with chemotherapy. Here, we showed that nivolumab combined with chemotherapy is a better choice for patients with unresectable esophageal SCC.
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Adverse events, Pan tumor: 13/15 #TumorBoardTuesday 📌Ipilimumab + Nivolumab ✨DART trial 📚@mdmanishshah https://t.co/zfsmsYohZw 📍For non pancreatic #NETCancer: ✨Basket trial🧺 💥40% response for high-grade tumors but no distinction btwn neuroendocrine carcinomas vs G3 tumors 💥50% G3-5 adverse events (Twitter) - May 2, 2023
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: 12/15 #TumorBoardTuesday #NETCancer Back to our case🔎 🔀 Treatment changed 💉Current treatment: Nivolumab3 + Ipilimumab1 🙏🏼 C3 completed, no toxicities reported to date 📆 Will see 👩🏻 for regular follow-up every 3 weeks (Twitter) - May 2, 2023
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Segmental Colitis Associated with Diverticulosis (SCAD). (Pubmed Central) - May 2, 2023
Interestingly, its appearance in some treated with monoclonal agents (eg., ipilimumab associated colitis) or infected with coronavirus-19 may have critical implications for its pathogenesis. This review further explores the implications of recognition of this pattern of colonic inflammatory disease, with relevance for physicians involved in both clinical practice and clinical trials of newer therapeutic agents.
- || Retrospective data, Review: Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. (Pubmed Central) - May 1, 2023
Therefore, clinicians should consider this evidence when developing an ICI immunotherapy regimen for lung cancer. https://www.crd.york.ac.uk/prospero, identifier CRD42023360931.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Tumor mutational burden, IO biomarker: A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (clinicaltrials.gov) - May 1, 2023
P2, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
https://www.crd.york.ac.uk/prospero, identifier CRD42023360931. Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
- | Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Yervoy (ipilimumab) / BMS
New P2 trial, Tumor mutational burden, IO biomarker: Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 1, 2023
P2, N=66, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | CP-506 / Convert Pharma
Enrollment open, Monotherapy: Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov) - May 1, 2023
P1/2, N=126, Recruiting, Sponsor: Maastricht University
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024 Not yet recruiting --> Recruiting
- vopratelimab (JTX-2011) / Concentra Biosci
Trial completion, Trial completion date, Trial primary completion date: Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - May 1, 2023
P1/2, N=4, Completed, Sponsor: Jounce Therapeutics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jan 2023 | Trial primary completion date: Apr 2024 --> Jan 2023
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer, Yervoy (ipilimumab) / Ono Pharma, BMS
Apologies. Meant regorafenib the Redos study and checkmate 511 for ipi Nivo in melanoma shows less toxicity but similar survival. (Twitter) - Apr 29, 2023
- ||| Really because I think a lot of examples where it doesn’t. Lonsurf run in, and pembro dosing and ipi Nivo melanoma vs renal dosing. Huge issue (Twitter) - Apr 29, 2023
- || renvistobart (BMS-986207) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov) - Apr 28, 2023
P1/2, N=241, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jan 2023 | Trial primary completion date: Apr 2024 --> Jan 2023 Trial completion date: Feb 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Clinical, IO biomarker: Wow, that is pretty amazing!!! I wonder if next steps might be to compare LAG-3 Relatlimab+Nivolumab combo vs Ipi+nivo for the same biomarker. Could help in making first line treatment choice!!! (Twitter) - Apr 27, 2023
- ||||| Clinical, Metastases: Ipi/nivo works for some pts w/ NEC. A young person w/ localized esophageal NEC, s/p CRT and resection. Metastatic recurrence, PR on FOLFIRINOX followed by substantial progression. Ipi/nivo per DART SWOG 1609 started but early prog within weeks, palliative RT and ipi/nivo cont. (Twitter) - Apr 27, 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change: A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma (clinicaltrials.gov) - Apr 27, 2023
P2, N=2, Active, not recruiting, Sponsor: University of Chicago
Trial completion date: Feb 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024 Recruiting --> Active, not recruiting | N=37 --> 2
- Yervoy (ipilimumab) / Ono Pharma, BMS
Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6753;
In this study, the immuno-infiltrating landscape was characterized based on pan-immune signatures using transcriptomic profile in GIST. The molecular subtypes derived from pan-immune signatures have the potential to predict the efficacy of immunotherapy.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Dissecting the relationship between ethnicity and response to checkpoint inhibitors in patients with acral melanoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6653;
The data from our prior small retrospective study suggested that non-Hispanic patients with ALM had low response rates to CPI presumably due to low TMB while interestingly, Hispanic patients, despite relatively low TMB have high response rates paralleling those seen in the overall cutaneous melanoma population. This data will provide the rationale to design prospective studies to investigate further how tumor micro-environment varies with ethnicity.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6626;
Adjuvant therapy was generally well tolerated, with manageable adverse events, consistent in type and incidence to those seen in clinical trials that allowed the approval for these compounds in adjuvant and metastatic scenarios. Prospective studies are needed to determine new biomarkers for the selection of those patients who could benefit to a greater extent from adjuvant therapies in resected high-risk melanoma.
- Yervoy (ipilimumab) / Ono Pharma, BMS
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6618;
Prospective studies are needed to determine new biomarkers for the selection of those patients who could benefit to a greater extent from adjuvant therapies in resected high-risk melanoma. Our analysis confirms the predictive value of a 3 biomarker Lasso Cox score predicated on CTLA4+ Treg, M-MDSC and CXCR3+/CD8+ T cell content in patient blood at baseline as it relates to adjuvant ipi treatment outcomes.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6613;
Maintenance of NIVO despite early toxicity during combination treatment appears to have a beneficial effect on patient survival. Therefore, it is extremely important to carefully monitor pts for toxicity, as early intervention helps to avoid severe toxicity and premature discontinuation of treatment.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Impact of antibiotics on survival outcomes and risk of gastritis/colitis in patients with advanced-stage melanoma receiving anti-PD-1 therapy. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6605;
Unlike previous studies, we found improved survival in patients receiving antibiotics during treatment and in those receiving antibiotics without anaerobic coverage. Our results demonstrate the need to further investigate specific antibiotic agents as well as antibiotic timing and their clinical impact on patients receiving ICI treatment.
- Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6604;
NAT induces better anti-tumor activity, leading to improved EFS and OS compared to AT, with similar safety profile. Phase 3 clinical trials with longer follow-up are warranted.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6594;
The efficacy of anti-PD-1+ ipilimumab combination therapy in Chinese patients tended to be inferior compared to global studies but was well tolerated. OS were good in cases with CR or PR.
- bempegaldesleukin (NKTR-214) / Nektar Therap, BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Eosinophilia in patients with melanoma under treatment with immune checkpoint inhibitor-based regimens. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6592;
The rate of eosinophilia was significantly higher in patients treated with nivolumab plus bempegaldesleukin (50.0%), followed by nivolumab plus ipilimumab (21.7%). This is the first study evaluating the association between the type of immunotherapy and the rate of eosinophilia in patients with melanoma and analysing the baseline characteristics of the patients as well as their diagnostic evaluation and management, course, and prognosis.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6589;
Imaging response was also strongly associated with both OS and TTNT irrespective of therapy received. These results may help inform treatment selection, and aid in counseling of advanced melanoma patients treated with first line ICI therapy in a routine clinical practice setting.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Relationship of adverse events after combined immunotherapy and treatment outcomes in patients with advanced melanoma: A multicenter experience in Poland. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6580;
Patients with advanced melanoma treated with combined immunotherapy who experienced irAEs have a more favorable outcome, which is even better in those with more episodes of toxicity. The type of irAEs may also have predictive value.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Patterns of care delivery and outcomes in patients with melanoma brain metastases treated with ipilimumab/nivolumab. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6579;
The majority of pts with MBM are ultimately treated with multimodality therapy. Advances in systemic therapies have provided meaningful clinical benefit that could allow a limited number of asymptomatic patients to forgo local therapy, but currently few pts are treated in this manner.
- Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6575;
One-third of the patients received treatment before BRAFm testing results were available and most of them were prescribed IO. These findings along with elevated ECOG scores, the proportion of 3+ metastases, and elevated LDH levels seen in TT patients, suggest TT is often offered to patients with a high disease burden in the current practice settings.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6572;
Patient factors including stage at treatment initiation, BRAF status, and steroid usage during treatment were not associated with significant variation in OS in this cohort. Most pts with recurrences remain disease free after additional local and/or systemic treatment.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Retreatment with nivolumab and ipilimumab with or without chemotherapy in patients with metastatic non-small cell lung cancer after progression on immune checkpoint inhibitor therapy. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6540;
Most pts with recurrences remain disease free after additional local and/or systemic treatment. Patients previously treated by ICI could be retreated by ICI combined with histology-driven chemotherapy in an individual approach, under certain circumstances, which are yet to be formally evaluated and determined.
- How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6508;
To our knowledge, this is the first such analysis in mNSCLC comparing efficacy and safety across PD-(L)1 based therapies. Results suggest PD-(L)1 CPI have similar treatment outcomes in mNSCLC, and PD-L1 expression may be more impactful on clinical benefit of monotherapy compared to CPI combination with chemotherapy.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Outcome analysis of immunotherapy and possible prognostic role of pretreatment neutrophil-lymphocyte ratio in lung cancer: An Appalachian study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6439;
IRAE may have a predictive role in survival, as we observed that patients with NSCLC developing IRAE had better survival rates. Ipilimumab-Nivolumab combination resulted in more IRAE than any other ICI.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6306;
Immunotherapy and TTF have reshaped the standard of care landscape over the past 27 years. With the enhanced understanding of molecular characteristics and mechanism of MPM, it is anticipated that ongoing immunotherapy combined with target therapy, chemotherapy or other novel treatment can improve the frontline and post-line therapeutic effect.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Incidence of immune checkpoint inhibitor induced myocarditis in patients with mesothelioma from a regional tertiary cancer centre covering a patient population of 2.6 million. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6303;
As patients treated with cICIs with abnormal b/l cardiac markers had an increased risk of developing ICI induced myocarditis, b/l cardiac markers could potentially be used to help stratify the risk of ICI induced myocarditis and inform treatment discussions. Further studies are now required.
- Real world data on immunotherapeutic outcomes in solid tumours. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5983;
Benefits of immunotherapy are not universal, best responses were noted in NSCLC, Bladder, and RCC. Identification of novel predictive biomarkers would improve clinical outcomes in solid tumours.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Improving the care of patients with lung cancer hospitalized with immune checkpoint inhibitor-related pneumonitis: Implementation of a clinical pathway algorithm. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5933;
While this change was not statistically significant, our multi-level approach was able to help increase the utilization of immunotoxicity tools on the OHM service. Continued education on the OHM service is needed to promote adherence to the developed pathway and help improve patient outcomes.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5722;
Continued education on the OHM service is needed to promote adherence to the developed pathway and help improve patient outcomes. Overall, PMB was associated with a CR,PR ratio of 5.6% (95% CI 0.01-0.10, I
- Votrient (pazopanib) / Novartis
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5719;
Pazopanib was associated with durable PFS and good tolerability when offered after PD or intolerance on lenvatinib in this retrospective analysis, warranting a randomized prospective study. >
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Retrospective analysis of NUT carcinoma: The Northwestern experience. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5718;
In our series, NC originating from the thyroid gland accounted for more cases than expected, thyroid NC patients were older than NC cases arising in other locations and with the more typical squamous histology. Despite relatively low PD-L1 staining, TMB, and MS status, our data suggests NMC tumors may be amenable to treatment with immune checkpoint inhibitors, warranting further investigation.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5361;
FDG PET/CT semi-quantitative parameters showed potential prognostic capabilities in pts with non-prostate mGU malignancies with bone +/- visceral metastases treated on a phase I study with CaboNivo +/- Ipi. Additional parameters and histologic subsets will be presented.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Immunotherapy-related toxicities: A retrospective analysis of barriers to prompt detection and initiation of treatment in renal cell carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5341;
Continuation of current practices can lead to further decreases in time to steroid treatment. This study can be used as a blueprint and expanded to further investigate irAEs in other solid tumors as well as contribute to management of the ever-evolving immunotherapy landscape.
- Use of immunotherapy-based combos in advanced renal cell carcinoma in a Galician center. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5336;
There are no statistically significant OS differences between IO-IO & IO-TKI. Immediate or delayed nephrectomy seem safe in selected patients.
- Yervoy (ipilimumab) / Ono Pharma, BMS
Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5333;
High HRD-RNA was associated with longer PFS for metastatic ccRCC patients undergoing ICI-treatment. A
- Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5325;
P=N/A
The model tests treatment combinations across multiple modes of action and quantifies cell response including viability, death, migration, infiltration and immune-surveillance. Future work aims to further develop the platform to match/predict patient responses in breast (NCT05435352), kidney, and other tumors.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5315;
This finding is consistent with the literature suggesting that muscle mass measurement provides an important prognostic biomarker for patients with mCCRCC. SMI could inform treatment selection and adoption of muscle measures when risk-stratifying this population should be considered.